Emergency department (ED) visits in women affected by leiomyomas, or uterine fibroids (UFs), are increasing, but hospital admissions for this patient population are decreasing, according to a study published in the journal Obstetrics & Gynecology.
However, when women seek care for bleeding-related symptoms, the chance of admission increases. Location, age, and method of payment also factored into ED visits and admissions.
Erica E. Marsh, MD, MSCI, who is chief of the division of reproductive endocrinology and infertility at the Center for Reproductive Medicine at Michigan Medicine Von Voigtlander Women’s Hospital, conducted the study along with colleagues. Researchers were looking for national trends and associated charges by hospitals, in addition to identifying causes of hospital admissions.1
The authors used data from the Healthcare Cost and Utilization Project (HCUP) Nationwide Emergency Department Sample database, the largest publicly available for all payers. They performed a retrospective examination of ED visits between 2006 and 2017 by women aged 18 to 55 years with a primary leiomyoma diagnosis as determined by ICD diagnosis codes.
Researchers also analyzed hospital charges, current procedural terminology codes, and secondary IDC diagnoses; they used a multivariate regression model to find admission predictors. “Gaining insight into the volume of these visits and drivers of admission could help redirect appropriate patients to alternative care settings, resulting in significant cost savings,” study authors wrote.1
Marsh and colleagues reported 533,963 ED visits for leiomyomas during the study period out of 487,688,338 total ED visits by women.1 Between 2006 and 2017, researchers said there was a 129% increase in ED visits for leiomyomas, from 28,732 to 65,685 visits.1
“The proportion of all ED visits that were for a primary diagnosis of leiomyomas also increased over the study period, from 0.079% in 2006 to 0.154% in 2017, suggesting that the increase was not simply from an increase in overall population volume,” researchers said. In contrast, admission rates fell from 23.9% in 2006 to 11.1% in 2017.1 Researchers noted that admission for all other diagnoses to the ED was only 8.5% during the study period.
Women aged 36 to 45 years accounted for 44.5% of ED and admissions for leiomyomas, while women aged 18 to 25 years had 3.4% of the share, according to the study. In addition, 36.1% of women coming to the ED were in the lowest income quartile, while women in the highest income quartile made up 16.4%.
Women from the geographic South were most likely to present to the ED (46.2%), while women from the Midwest (12.2%) were least likely. Private insurance was the most common payment method (38.3%), followed by Medicaid (27.1%) and self-pay (24.4%).
Researchers said uninsured patients were least likely to be admitted (Medicare: odds ratio [OR] 1.37, 95% CI 1.21-1.54; Medicaid: OR 1.26, 95% CI 1.16-1.36; private: OR 1.44, 95% CI 1.32-1.56).1
Marsh and colleagues said the decline in hospital admissions indicates that many ED visits for leiomyomas could be treated in non–acute care settings. They also noted that rates of admission varied greatly by location and method of payment, perhaps because of local policy or biases of health care professionals.
Bleeding was a strong factor in admissions, with the symptom presentation increasing admission odds 15-fold, according to the study.
“Improving our understanding of patients with leiomyomas who present to the ED, but are not admitted, will help target interventions to better care for these patients in the outpatient setting and ultimately reduce the burden of leiomyomas for both patients and society,” researchers said.
Reference
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More
Study finds relugolix-CT Improves HMB in Black women
February 19th 2024Recent research highlights the efficacy and safety of relugolix combination therapy in managing uterine fibroid-associated heavy menstrual bleeding specifically among Black women, demonstrating outcomes comparable to the broader population.
Read More